Industry Overview - The biotech industry has shown resilience amid global trade tensions, with ongoing geopolitical issues presenting challenges, yet the demand for innovative medical treatments remains strong [1] - Strategic collaborations and acquisitions are increasingly common as large pharma and biotech companies seek to expand their product portfolios and pipelines, particularly in the context of AI-driven drug discovery [2][9] - The Zacks Biomedical and Genetics industry is currently ranked 86, placing it in the top 35% of over 246 Zacks industries, indicating a decent outlook driven by consistent demand for medical advancements [15] Market Trends - The focus on high-profile drug performance and innovative pipeline development is critical, with significant R&D expenditures required to create breakthrough treatments [6] - Successful commercialization is essential for drug uptake, often leading smaller biotech firms to collaborate with larger companies for shared sales or royalties [7] - The recent emphasis on AI technology for drug discovery is expected to attract further investment into the biotech sector [11] Company Performance - Exelixis, Inc. (EXEL) is positioned well with its lead drug, Cabometyx, which is gaining traction in the oncology market, and its shares have surged 31% year to date [35][36] - Verona Pharma (VRNA) has seen a 94.8% increase in shares year to date, driven by the uptake of its drug Ohtuvayre for COPD, with further growth anticipated [24] - Alkermes (ALKS) is benefiting from strong sales of its proprietary drugs and has a Zacks Rank of 1, with EPS estimates for 2025 rising to $1.79 [26][27] - Immunocore Holdings (IMCR) focuses on TCR bispecific immunotherapies and has gained 11.4% year to date, with ongoing studies expected to enhance its market position [30][32] - Kiniska Pharmaceuticals (KNSA) is experiencing growth with its FDA-approved drug Arcalyst and has seen a 37.7% increase in shares [39][40]

RIYADH, Saudi Arabia and ISTANBUL and OXFORDSHIRE, United Kingdom, June 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced that they have been appointed by Immunocore (Nasdaq: IMCR) as the distribution and commercialization partner for KIMMTRAK, for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma, in Turkey and across the Middle East, North Africa, Caucasus and the ...

Transformative immunomodulating medicines for patients May 2025 1 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may", "will", "believe", "expect", "plan", "anticipate", "estimate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements ...

Core Insights - Immunocore Holdings plc is a commercial-stage biotechnology company focused on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases [1][3] - The company will participate in the 2025 Jefferies Global Healthcare Conference, indicating its ongoing engagement with investors and the healthcare community [1][2] Company Overview - Immunocore is pioneering a novel class of TCR bispecific immunotherapies known as ImmTAX, aimed at treating a wide range of diseases [3] - The company has a robust pipeline with multiple active clinical and pre-clinical programs across oncology, infectious diseases, and autoimmune diseases [3] - KIMMTRAK, Immunocore's leading oncology TCR therapeutic, is approved for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in several regions including the US, EU, Canada, Australia, and the UK [3]

Immunocore (IMCR) is witnessing a strong sales uptake for its sole marketed drug, Kimmtrak (tebentafusp-tebn), which is approved for treating patients with unresectable or metastatic uveal melanoma (mUM).Kimmtrak is approved in 39 countries, including the United States, the European Union, Canada, and others. The product has been launched in 26 countries worldwide and continues to be the standard of care for mUM in most markets where it has been launched.Kimmtrak generated sales worth $310 million in 2024, ...

Core Insights - Immunocore reported a strong revenue performance in Q1 2025, with net revenues of $93.9 million, reflecting a 33% year-over-year growth, primarily driven by the sales of KIMMTRAK [1][2][3] Financial Results - Total net product revenue from KIMMTRAK was $93.9 million in Q1 2025, an increase from $70.3 million in Q1 2024, with $56.6 million generated in the United States, $32.8 million in Europe, and $4.5 million in international regions [3][24] - Research and development expenses for Q1 2025 were $56.5 million, slightly down from $57.5 million in Q1 2024, while selling, general, and administrative expenses increased to $40.2 million from $39.3 million [4][25] - The company achieved a net income of $5.0 million in Q1 2025, compared to a net loss of $24.4 million in the same period in 2024, with basic and diluted income per share at $0.10, up from a loss of $(0.49) [5][20] Product and Market Updates - KIMMTRAK is approved in 39 countries and launched in 26 countries for HLA-A*02:01 positive patients with metastatic uveal melanoma, continuing to be the standard of care in most markets [6][36] - The company is focusing on three key growth areas for KIMMTRAK: global expansion in metastatic uveal melanoma, potential expansion into second-line advanced cutaneous melanoma, and adjuvant uveal melanoma [7] - KIMMTRAK net product sales in the U.S. grew by 13% year-over-year, with increased demand driven by community outreach and new country launches in Europe and international regions [8] Research and Development Progress - Immunocore is on track for the Phase 3 TEBE-AM trial to complete enrollment in the first half of 2026 and for dose selection in the Phase 3 PRISM-MEL-301 trial in the second half of 2025 [1][14] - Initial multiple ascending dose data for the HIV functional cure candidate was presented at CROI 2025, with ongoing dose escalation [1][22] - The company is advancing its PRAME portfolio, with brenetafusp being evaluated in combination with nivolumab in a Phase 3 trial for first-line advanced cutaneous melanoma [10][15]